The neurobehavioural disorder drug developer sourced funding from investors including Scripps Research, Alphabet, Alexandra Real Estate Equities and Johnson & Johnson in the round.
Blackthorn Therapeutics, a US-based developer of treatments for neurobehavioural disorders, has raised $76m in a series B round that included corporates Johnson & Johnson, Alphabet and Scripps Research Institute.
Alexandria Venture Investments, the venture capital arm of life sciences real estate manager Alexandra Real Estate Equities, also took part, as did Polaris Partners, Premier Partners, Vertex Ventures HC, Altitude Life Science Ventures, Mercy Fund, Arch Venture Partners and Biomatics Capital.
Medical research organisation Scripps Research Institute invested in Blackthorn directly, while internet and technology…
